Scientific Advisory Board

Expert Network

Scientific Advisory Board

The Helixgate Scientific Advisory Board is being selectively assembled to guide the intersection of biotechnology, advanced computational systems, and next-generation research infrastructure. This board will consist of leading scientists, researchers, and industry experts contributing strategic insight across drug discovery, clinical advancement, and scientific innovation.

Board Formation in Progress

We are currently in the process of onboarding a limited number of advisory board members across key disciplines within the life sciences sector. Helixgate is focused on building a high-caliber advisory group composed of individuals with deep expertise and active involvement in advancing scientific discovery and real-world application.

Core Advisory Domains

Drug Discovery & Translational Science

Small molecule, biologics, and therapeutic development.

Clinical Research & Trials

Phase I–III execution, regulatory pathways, and patient outcomes.

Computational Biology & Systems

AI/ML integration, modeling, simulation, and data-driven discovery.

Biotech Infrastructure

Life science campuses, lab environments, and R&D ecosystems.

Regulatory & Compliance Strategy

FDA pathways, approvals, and global regulatory alignment.

Capital & Strategic Growth

Investment strategy, scaling biotech companies, and partnerships.

Advisory Profiles Being Considered

Senior Scientists at leading pharmaceutical organizations
Directors of Research & Development (R&D)
Clinical trial and regulatory specialists
Computational biology and AI research leaders
Founders and executives of biotech companies
Institutional investors in life sciences

Role of the Scientific Advisory Board

The advisory board provides strategic guidance on emerging scientific trends, validates key areas of focus within the publication, and contributes to the broader direction of Helixgate’s intelligence and research initiatives.

Members may participate in editorial guidance, topic validation, and strategic discussions surrounding the future of biotechnology and advanced systems.

By invitation and qualification only

Advisory Participation

Helixgate Biotech Review is actively engaging with select individuals for advisory board participation. If you are a leader in biotechnology, research, or advanced scientific systems and are interested in contributing to a high-level advisory initiative, we welcome confidential inquiries.

Media Kit

Access our comprehensive media kit to understand our positioning, audience, and partnership opportunities.

Helixgate maintains a high standard of editorial integrity, focusing on accuracy, strategic insight, and meaningful industry contribution.

Stanford University

Dr. Wei leads Stanford’s computational biology division, specializing in machine learning applications for genomics and precision medicine.

ETH Zurich

Prof. Larsson is a pioneer in synthetic biology and metabolic engineering, with a focus on cell factory design for sustainable biomanufacturing.

Genentech

Dr. Osei oversees computational drug discovery programs at Genentech, integrating AI and structural biology for novel therapeutic development.

UC Berkeley

Prof. Nakamura is a leading figure in CRISPR technology development and genome engineering, with over 200 peer-reviewed publications.

Twist Bioscience

Dr. Fernandez leads scientific strategy at Twist Bioscience, driving innovation in synthetic biology and next-generation sequencing technologies.

University of Cambridge

Prof. Ashford specializes in structure-based drug design and has contributed to multiple approved therapeutics over a distinguished career.

Founding Scientific Advisory Board - In Formation

Helixgate Biotech Review is establishing a distinguished Scientific Advisory Board composed of leading scientists, biotechnology executives, research innovators, and industry experts who help guide the editorial direction and scientific integrity of our platform.

The advisory board will support Helixgate Biotech Review in identifying emerging breakthroughs across biotechnology, drug discovery, life sciences infrastructure, and next-generation scientific innovation.

Advisors will contribute expertise in areas including:

Drug Discovery & Translational Medicine
Molecular Biology & Genomics
Biopharmaceutical Development
Advanced Therapeutics
Bioengineering & Synthetic Biology
Life Sciences Infrastructure & Innovation Ecosystems
Computational Biology & Scientific Platforms

The Scientific Advisory Board will help ensure that Helixgate Biotech Review maintains high scientific standards, global perspective, and forward-looking analysis of the technologies shaping the future of medicine and biological research.

Founding Advisors - Announcements Coming Soon

Helixgate Biotech Review is currently engaging respected leaders across academia, biotechnology companies, and research institutions to join the Founding Scientific Advisory Board.

Advisor announcements will be published here as appointments are finalized.

Advisory Board Participation

We welcome discussions with individuals who have significant experience in:

If you are interested in contributing to the Scientific Advisory Board, please contact:

Expert Network